Completed PHASE2 INTERVENTIONAL 2-arm NCT01051817

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

A Randomized, Multi-center, Double-blind, Proof-of-concept Study to Assess the Effect of Multiple Infusion of AIN457 (10 mg/kg) Versus Placebo on Disease Activity as Measured by MRI Scans Over a 24 Week Period in Patients With Relapsing-remitting Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Conditions RRMS Relapsing-remitting Multiple Sclerosis

Interventions AIN457 Placebo

Updated 6 times since 2017 Last updated: Feb 12, 2015 Started: Dec 31, 2009 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01051817, this PHASE2 trial focuses on RRMS and Relapsing-remitting Multiple Sclerosis and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Hradec Králové, Czechia , Kazan', Russia , Kharkiv, Ukraine , Kiev, Ukraine , Moscow, Russia , Nizhny Novgorod, Russia , Odesa, Ukraine , Ostrava, Czechia , Ostrava-Moravska Ostrava, Czechia , Prague, Czechia and 3 more locations